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Background: P73 belongs to the p53 family of cell survival regulators with the corresponding locus Trp73
producing the N-terminally distinct isoforms, TAp73 and DeltaNp73. Recently, two studies have implicated the
murine Trp73 in the modulation in phospho-tau accumulation in aged wild type mice and in young mice modeling
Alzheimer’s disease (AD) suggesting that Trp73, particularly the DeltaNp73 isoform, links the accumulation of
amyloid peptides to the creation of neurofibrillary tangles (NFTs). Here, we reevaluated tau pathologies in the same
TgCRND8 mouse model as the previous studies.
Results: Despite the use of the same animal models, our in vivo studies failed to demonstrate biochemical or
histological evidence for misprocessing of tau in young compound Trp73+/- + TgCRND8 mice or in aged Trp73+/-
mice analyzed at the ages reported previously, or older. Secondly, we analyzed an additional mouse model where
the DeltaNp73 was specifically deleted and confirmed a lack of impact of the DeltaNp73 allele, either in
heterozygous or homozygous form, upon tau pathology in aged mice. Lastly, we also examined human TP73 for
single nucleotide polymorphisms (SNPs) and/or copy number variants in a meta-analysis of 10 AD genome-wide
association datasets. No SNPs reached significance after correction for multiple testing and no duplications/
deletions in TP73 were found in 549 cases of AD and 544 non-demented controls.
Conclusion: Our results fail to support P73 as a contributor to AD pathogenesis.
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Neuropathological staging of Alzheimer’s Disease (AD)
tissue indicates a preeminent role for sequential tau de-
position, and tau pathology is well correlated with de-
mentia scores [1-3]. On the other hand, genetic studies
indicate the primacy of changes in Aβ synthesis as a key
causal factor that is often described as being “upstream”
of tau. Because of the exponential incidence of AD in
the industrialized countries, defining links between Aβ
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distribution, and reproduction in any mediumtheoretical and practical points of view. To this end,
introduction of mutations affecting APP processing into
transgenic animal models can induce florid amyloid path-
ology and modest neuritic tau pathology only in the im-
mediate vicinity of plaques [4-7], but is not associated
with the development of florid neurofibrillary tangles
(NFTs) as characteristically seen in AD. This inability of
APP transgenic mice to display florid tau pathologies at
sites distal to Aβ assemblies is a disadvantage in contexts
where candidate therapeutics are being tested and has led
to increased interest in double- and triple-transgenic
models of human neuropathologies [8-10]. Co-existing
and potentially synergistic Aβ and tau pathologies can be
obtained by simultaneously introducing separate human
APP and tau transgenes (albeit often using a mutant form
of human tau), or by delivering Aβ into the centraltral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Vardarajan et al. Molecular Neurodegeneration 2013, 8:10 Page 2 of 14
http://www.molecularneurodegeneration.com/content/8/1/10nervous system of TgTau mice [8,11-13]. While the poten-
tial of mutant and wild type (wt) human tau to form NFTs
in vivo is well established [14-16], progress on attaining an
analogous situation for endogenous murine tau protein
has proven more challenging. The origin of this
attenuated pathogenic potential of the murine protein is,
however, not clear as both recombinant human and
mouse proteins are able to form tangle-like structures
in vitro [17] and, in vivo, hyperphosphorylated mouse tau
accumulates in dystrophic neurites adjacent to amyloid
plaques such as, in sections from TgCRND8 mice [4]. Be-
sides “3R” and “4R” tau mRNA splicing variants (encoding
different numbers of microtubule binding domains) under
developmental and neuroanatomical control ([18] and
references therein), one possibility for the failure of wt
mouse tau to form NFTs is a distinction between mice
and humans within a chemical pathway that acts to link
Aβ accumulation to tau. In this context, the finding that
mice haploinsufficient for the murine Trp73 locus, a
member of the Trp53 gene family enriched in the nervous
system, are prone to develop tau pathology in presence of
an APP transgene [19] attracted a degree of attention [20].
In addition to the importance of this biological question,
the young age of the 1.5 to 2-month old animals reported
to have abnormal tau species derived from the wt murine
tau expressed at endogenous level was notable [19].
Plaque onset within 100% of animals is typically at 3
months of age in TgCRND8 mice [4] and 1.5-2-month
time-points are also earlier than that reported for
onset of pathology in several transgenic mouse lines
overexpressing germline mutant forms of tau [11,16,21].
In consequence, we were drawn to reevaluate tau patholo-
gies reported in Trp73+/-/TgCRND8 compound transgenic
mice [19,22]. For this purpose we used a series of tau-
based protein and histochemical assays in compound
transgenic and control mice of the same origin of the
same age or older than those used in the prior report. Our
studies failed to detect convincing pathologies in cohorts
of compound transgenic mice. Also, because other studies
found borderline evidence for an association between gen-
etic or copy number variants in the human p73 gene
(TP73) and risk for AD [23,24], we evaluated the possible
association of single nucleotide polymorphisms (SNPs)
and copy number variants (CNVs) in the human TP73
gene with AD in several large datasets. The results
presented here fail to define a genetic association between
the p73 locus and AD pathology in mouse models and in
human cohorts.
Results
Studies in Trp73+/- + TgCRND8 compound mutant mice
To assess and/or replicate the results obtained previ-
ously [19,22], we obtained mice bearing the same null al-
lele of murine Trp73 used in the original report, andintercrossed these animals with the TgCRND8 line of
APP transgenic mice. We note here that high levels of
expression of APP695 are associated with increased
mortality in the parental TgCRND8 mice, as is the case
for other TgAPP mice. This effect is not necessarily
dependent upon the inclusion of familial AD mutations
within APP that predispose to amyloid formation, but
can be influenced by inbred strain background [4,25-27].
In our studies the resultant C3H/C57BL6 hybrid genetic
background in the compound mice is similar to
backgrounds used previously to study TgCRND8 mice
[4]. Compound Trp73+/- + TgCRND8 animals generated
by our crosses expressed the APP transgene appropri-
ately (compared to TgCRND8; Figure 1 rows 1 and 3)
and, at weaning, 15 compound mice were observed (ver-
sus 12 expected) out of a total of 49 mice. The rate of
occurrence of the postnatal mortality effect in the Trp
73+/- + TgCRND8 compound mutant mice (4 events –
d35, d44, d49, d65 - out of 15 animals genotyped) was
not distinguishable statistically from TgCRND8 mice
with a homozygous wild type (wt) Trp73 genotype (3
events - d30, d53, and d73 - out of 10 genotyped TgCRND8
neonates), assessed here up to postnatal day 110.
Trp73+/- + TgCRND8 compound mutant mice, along
with age-matched control Trp73+/-, TgCRND8 and wild
type littermates, were then examined for tau alterations.
Cohorts of adolescent mice were either of the same age
(45-60 days) or older (70 days) than mice described by
Wetzel et al [19]. Four well-characterized antibodies
detecting phospho-specific epitopes of the endogenous
mouse tau protein were used for analyses of biochem-
ical and immunohistochemical alterations in the com-
pound mice (AT8, CP13, AT180 and PHF1). MC1, a
conformation-specific antibody, was also used in some
immunohistochemical analyses. As a positive control
for the analyses of pathological processing and depos-
ition of murine tau in the compound Trp73+/- +
TgCRND8 mice, we used mice expressing either P301L
or G272V/P301S mutant tau transgenes (designated
TgTauP301L and Tg30tau, respectively), both of which
develop extensively characterized neuronal tau patholo-
gies [28-30] (Figure 1, row 3). In the former case the tau
accumulation extends to glia and oligodendrocytes, pro-
viding a broad point of reference for tau pathologies.
Biochemical analysis of our compound Trp73+/-
+ TgCRND8 mice (45-70 day-old) failed to demons
trate significant levels of insoluble tau species with
four phospho-specific anti-tau antibodies (Figure 1;
Additional file 1: Figure S1 for a longer autoradiographic
exposure), whereas insoluble tau species were detected
in the TgTauP301L control mice. Tau immunostaining of
hippocampus and frontal cortex (the two main brain
regions displaying pathology in AD brains and animal
models) failed to reveal any staining in paraffin-embedded,
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Figure 1 Biochemical analysis of tau species in control and compound mutant young mice. The three columns display protein samples
derived from litters of increasing ages (45, 60 and 70 days old). The human APP695 transgene (“HuAPP”) and Trp73 genotypes were confirmed by
PCR-based methodologies (top two rows) as described in material and methods. Western blot analysis is shown for transgene-encoded human
APP (row 3: 6E10 antibody), with total tau (row 4) and actin (row 5) immunoblots serving as a loading control in soluble fractions. Tau antibodies,
AT8, AT180, CP13 and PHF-1 (rows 6-9, respectively), were used to evaluate pathological forms of tau in each sample in insoluble fractions. A tau
transgenic sample (left-hand lane) was included in the immunoblot series for each time-point as a positive control (TgTauP301L mouse, age 540
days). “+/-“ in the case of Trp73 and TgAPP indicates that these mice were heterozygous for null allele and hemizygous the TgCRND8 APP
transgene array, respectively. Loading controls (“Loading”; row 10) consist of images of Ponceau red-stained membranes taken immediately
after blotting.
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either at (45-60 days old) or after (70 days old) the ages
reported by Wetzel et al. (Figure 2A and Additional file 2:
Figure S2). These analyses were performed with AT8,
CP13 MC1 and AT180 antibodies. As anticipated, novel
tau pathologies were absent in negative control Trp73+/-
and Trp73+/+ littermates (Figure 2A and Additional file 2:
Figure S2), as was the case for TgCRND8+/- littermates, in
accord with previous analyses [4] (Additional file 2: Figure
S2 and data not shown). In contrast, florid tau pathologies
were detected in sections from TgTauP301L control animals
processed in parallel. As a further control we assessed
amyloid plaques and any associated dystrophic changes.
As anticipated from our earlier studies, the time period
60-90 days is on the cusp for detection of plaques in
TgCRND8 mice, and we were unable to detect amyloid
deposits in 60 day-old compound transgenic animals (data
not shown). Sparse amyloid deposits were present in 70
day-old compound transgenic animals (Figure 2B), as
was the case for TgCRND8 mice, and the analysis of
these 70 day-old animals verified our ability to detect
tau immunostaining in the form of dystrophic neurites
in animals bearing the TgCRND8 transgene array
(Figure 2B), demonstrating that the genetic background
used for these experiments is not refractory per se to the
development of tau pathologies.
In addition to paraffin-embedded tissue we also
performed immunostaining on frozen brain sectionsfrom 85 day-old compound mice using three phospho-
specific tau antibodies (AT8, CP13 and PHF1) and with
one conformation-specific antibody (MC1). Our results
were negative with MC1 and PHF1 antibodies, while AT8
and CP13 antibodies (which have overlapping epitopes)
yielded some staining of cortical neurons (Figure 3A). How-
ever, this staining differed from the focal tau pathologies
evident in TgTauP301L control mice (Figure 3A, panel v).
To assess whether our mouse cohorts had a slowed
disease progression, additional analyses were performed
on animals approximately four times older than the mice
described by Wetzel et al. Here immunoblots show that
9 month-old Trp73+/- mice have no signal differences in
detergent insoluble fractions probed with AT8 and
AT180 antibodies (Figure 3B) compared to wild type
littermates. Presence of an APP transgene in a Trp73+/-
mouse (i.e. a compound mouse of the same genotype as
analyzed in Figure 1) did not have an obvious impact on
the properties of these tau species. Interestingly, the ma-
terial in the soluble tau fractions (Additional file 3:
Figure S3) showed minor species of slower electrophor-
etic mobility in Trp73+/- animals compared to wild type
littermates, as detected with AT8 and CP13 antibodies.
Similar species were evident in the compound mouse of
the same age. No such distinction from wt controls was
detected with PHF1 or AT180 antibodies.
A direct effect of Trp73 hemizygosity on tau pathology
was also reported in aged mice (16-18 months),
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Figure 2 Immunohistochemical analysis of tau species in control and compound mutant young mice. A: Tau pathology was assessed
histologically in the hippocampal formation (top; 4 x objective) and cortex (bottom; 10 x objective). The left-hand column shows a control tau
transgenic mouse (TgTauP301L) with tau-positive astrocytic plaque and neurofibrillary tangle morphologies. Immunodetected structures are
denoted by brown (DAB) staining, in accord with previous analyses of mice of this age (540 days) [28]. No staining is apparent in compound
mutant mice aged 60 days (2nd column) or in Trp73+/- or wild type aged matched littermate controls (3rd and 4th columns, respectively) for AT8
and CP13 phospho-tau specific antibodies. B: Detection of neuritic pathology. Left hand field (4x) represents the area of hippocampus and cortex
from a sagittal section of 70 day-old compound transgenic mouse bearing a total of 5 amyloid plaques (arrows) visualized with 6E10 antibody.
Right hand panel (40x) shows one of the cortical plaques (grey arrow, left panel) that has developed neuritic tau pathology. The plaque vicinity is
shown (circle with a dashed line) and the neuritic pathology is manifest by dot-like immunostaining within the plaque (see also Additional file 2:
Figure S2).
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This phenotype was attributed to lack of DeltaNp73, the
sole p73 isoform present within the central nervous sys-
tem [31]. To investigate this observation, we first carried
out RT-PCR experiments to assess that the DeltaNp73
transcripts deriving from the promoter in intron 3 of the
Trp73 locus accounted for all p73 mRNAs expressed in
the aged mouse brain; this proved to be the case (data not
shown). Next, we examined Trp73+/- mice from our own
cohorts at similar ages, and subsequently we analyzed
aged mice with a selective knockout of the DeltaNp73
isoform [32]. In 17 month-old Trp73+/- mice, a minor
fraction of tau immunoreactivity detected with AT8 and
AT180 antibodies in insoluble fractions was qualitativelydifferent in the Trp73+/- mouse compared with control
samples from TgTau mice encoding the 2N, 4R isoform of
human tau (Figure 3C), but by standard histological
analysis of paraffin-embedded fixed tissue we were unable
to detect any abnormal tau structures in the Trp73+/-
mice. Here we used antibodies recognizing abnormally
phosphorylated tau species (Figure 3D). In a DeltaNp73-
specific knockout mouse model where both heterozygous
and homozygous DeltaNp73 deficient mice survive to
adulthood [32], brains were examined from old (15-24
months) DeltaNp73 heterozygous mice and from wild
type littermates. Of importance, our analyses also
included DeltaNp73 homozygotes, hence going beyond
the hemizygous state reported in prior analyses [19].
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Figure 3 (See legend on next page.)
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Figure 3 Biochemical and histochemical analysis of tau species in older compound and Trp73 mutant mice. A: Fluorescent
immunostaining of a 85 day-old compound Tg Trp73+/- plus TgAPP+/- mouse hemizygous for the TgCRND8 transgene array (i-iv) with tau
antibodies AT8, CP13, PHF1 and MC1. Decreasing amounts of somatodendritic staining are present with AT8, CP13 and PHF1 antibodies,
respectively. Thread-like staining is not seen. Staining with MC1 (iv) may correspond to detection of blood vessels and a similar pattern was
apparent with an anti-Aβ antibody 6E10 applied to a TgTauP301L mouse lacking an APP transgene (not shown). Panel v shows a section,
processed in parallel, from a TgTauP301L mouse. Note that the panels i-iv were overexposed compared to panel v to demonstrate intensity
differences between pathological features and neuroanatomical structures: a tangle bearing neuron is shown in the granular layer of the dentate
gyrus (horizontal arrow) and glial plaques in the subiculum and molecular layer (vertical arrows). B: Western blot analyses of phospho-specific tau
species in insoluble protein fractions derived from animals at 270 days of age. Tau antibodies, AT8 and AT180, (rows 1-2, respectively), were used.
C: Insoluble tau fractions of brain homogenates prepared from a Trp73+/- mouse at age 17 months were examined by western blotting with
antibodies as labeled. D: Histochemical analyses with AT8 and CP13 antibodies of a Trp73+/- mouse at age 17 months did not reveal tau
immunostaining. Positive controls are as per Figure 2A. An age-matched wt mouse is also shown for these analyses of paraffin-embedded tissue.
4 x and 10 x objective was used for hippocampus and cortex, respectively. Loading controls in B and C were as per Figure 1.
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samples did not differ significantly from that in control
samples, whereas strong somatodendritic phosphotau
immunoreactivity and Gallyas positive tangles were evi-
dent in neurons of tau (Tg30tau) control transgenic
mice analyzed in parallel (Figure 4A). Moreover, we
were not able to detect any accumulation of insoluble
hyperphosphorylated tau by immunoblotting in homo-
zygous or hemizygous DeltaNp73-deficient animals
(Figure 4B).
A further experimental variable between our study and
the previous reports concerns the mode of euthanasia.
In the study presented to this point, mice were euthanized
by cervical dislocation while Wetzel et al. and Cancino et
al. used anaesthetic (sodium pentobarbital) overdose. Pre-
vious studies by other groups have shown that anaesthesia
can induce tau immunoreactivity for antibodies AT8,
AT180, and CP13 even in the absence of human tau or
APP transgenes [33]. In experiments here we examined
the tau pathology in 45 day-old adolescent wt mice (C3H/
C57BL6 background) euthanized either by cervical dis-
location or sodium pentobarbital administration. Our
results showed an increased phosphorylation of tau in
detergent insoluble extracts from sodium pentobarbital-
treated animals versus animals euthanized by cervical dis-
location (as used for all our studies prior to this point)
(Additional file 4: Figure S4). Thus an effect of euthanasia
by anesthetic overdose can generate phospho-tau species
(encompassing Ser 202 and 396/404 as detected by CP13
and PHF1 antibodies) at the time of tissue harvest.
Assessing genetic association analyses in human
populations
To examine the contribution of the P73 locus in the de-
velopment of AD in humans, we tested whether there
was meaningful support for 54 genotyped or reliably
imputed SNPs in TP73 to be a risk factor for AD. This
analysis used 10 genome wide association studies
(GWAS) datasets (listed in Table 1) that constituted the
discovery sample in a previously published GWAS [34].Inspection of results within individual datasets revealed
28/540 (5.2%) of the comparisons were nominally signifi-
cant (see Additional file 5: Table S1) which is almost
exactly the number of results expected to attain this
level of significance due to chance alone. More than
one-half of the significant findings were observed in one
of the smallest datasets (ADNI). None of the SNPs were
nominally significant in the meta-analysis (Table 2). In
addition, there was no evidence for association on a
gene-based level using the VEGAS method (P>0.95). Fi-
nally, no deletions were discovered among 549 AD cases
and 544 non-demented controls as a cause of the poten-
tial haploinsufficiency of the TP73 locus as inferred by
Wetzel et al [19]. These CNV experiments also did not
identify any duplication events encompassing TP73.
Discussion
P73 belongs to the p53 family of cell survival regulators
and presents several isoforms controlled by two main al-
ternative promoters leading to transactivating (TAp73)
and N-terminally truncated (DeltaNp73) isoforms [35].
TAp73 and DeltaNp73 were previously reported to exert
pro- and anti-apoptotic effects, respectively, in different
cellular systems including the central nervous system
[32,36]. P73 is required for correct development of the
cerebrum, with hydrocephalus and hippocampal dysgenesis
occurring in complete p73 knockout mice [37,38]. Lack of
P73 is inferred to result in a loss of the protective functions
and this concept has been explored in the specific context
of the neurodegenerative changes of AD [19,22]. Hence, in
a series of biochemical and histological analyses we
attempted to examine and extend these potentially import-
ant interactions between P73 and Aβ in the setting of a pre-
viously described mouse model [19]. Intercrosses of two
genetic stocks with distinct neurological deficits is a com-
mon strategy in neurodegenerative disease research and
can result in novel or enhanced phenotypic traits. In prac-
tice, though using the same APP transgene and the same
Trp73 null allele, we have not been able to demonstrate
AD-like tau pathologies in compound mutant mice, nor in
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Figure 4 Analysis of tau species in aged delta NP73 null mice. A: Histochemical analysis of the hippocampus of 17 month-old DeltaNp73
homozygous mutant mouse (middle row) and a wildtype littermate control (bottom row). Immunohistochemitry with AT8 and PHF-1 antibodies
(left and middle columns, respectively) and Gallyas staining (right column) were used to examine tau pathology in these mice. Tau transgenic
Tg30 mice were used as a positive control for staining (top row) with Gallyas-positive aggregates and a somatodendritic accumulation of
phosphotau being observed in TgTau but not in DeltaNp73 mice. B: Immunoblot analysis of 17 month-old DeltaNp73 hemizygous and
homozygous mutant mice using phosphotau specific antibodies. Tau transgenic Tg30 mice were used as a positive control (left lane). Loading
controls (bottom row) consist of images of Ponceau red-stained membranes taken immediately after blotting.
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described by the Wetzel et al. study, nor in mice homo-
zygous null for DeltaNp73. We are now considering the-
oretical and practical parameters that may explain these
discrepancies.
One potential divergence with the initial report [19]
concerns the genetic backgrounds in the respective
cohorts, which are enriched for the 129SvJae and C3H/
C57BL6 strains for the Wetzel et al. and the presentstudy, respectively, and which might affect the nature
and tempo of tau pathology. However, there are three
observations here that bear on this issue. First, the C3H/
C57BL6 genetic background is able to support the
formation of hyperphosphorylated tau in dystrophic
neurites in TgCRND8 mice ([4] and Figure 2B). Second,
we did not detect any tau pathology in the homozygous
null DeltaNp73 model, which contains a contribution
from the 129Sv background, being a mixture of 129SvJ
Table 1 Subject characteristics
Cohort AD cases Controls (N)
N Age at onset APOE ε2/ε3/ε4 N Age at exam APOE ε2/ε3/ε4
(mean ± SD) (allele %) (mean ± SD) (allele %)
ACT 566 83.90 (4.8) 0.05 / 0.69 / 0.26 1696 81.08 (6.0) 0.08 / 0.81 /0.11
ADC1 1566 72.47 (7.1) 0.03 / 0.55 / 0.42 515 75.00 (8.0) 0.08 / 0.76 / 0.16
ADC2 738 73.19 (7.1) 0.03 / 0.57 / 0.39 160 75.68 (7.9) 0.09 / 0.75 / 0.16
ADNI 268 75.30 (7.2) 0.03 / 0.55 / 0.42 173 78.6 (5.5) 0.08 / 0.79 / 0.14
GenADA 669 74.59 (6.2) 0.04 / 0.58 / 0.38 713 74.21 (7.0) 0.08 / 0.79 / 0.13
MIAMI 1186 74.06 (7.8) 0.03 / 0.61 / 0.36 1135 74.00 (8.3) 0.08 / 0.80 / 0.12
MIRAGE 509 71.16 (6.5) 0.04 / 0.60 / 0.36 753 72.04 (7.2) 0.06 / 0.72 / 0.23
NIA-LOAD 1811 73.57 (6.7) 0.02 / 0.51 / 0.46 1575 73.99 (8.5) 0.07 / 0.73 / 0.20
OHSU 132 86.10 (5.5) 0.07 / 0.70 / 0.23 153 83.86 (7.6) 0.10 / 0.82 / 0.08
TGEN 864 74.91 (7.2) 0.04 / 0.57 / 0.40 493 80.19 (8.7) 0.10 / 0.79 / 0.11
TOTAL 8309 – – 7366 – –
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over four times older than those reported by Wetzel
et al. failed to demonstrate abnormal tau species
(Figure 3B). Also, in a report by Cancino et al. [22],
Trp73+/- -dependent tau immunostaining was noted in
two distinct genetic backgrounds, C129129SvJae and
C57/BL6. Overall, these findings decrease the impetus to
consider (hypothetical) strain background effects as a
crucial determinant of the widely divergent results.
A second potential divergence between the two sets of
studies is the euthanasia protocol: sodium pentobarbital
overdose [19,22] versus cervical dislocation (used here).
Previous studies have shown that phospho-specific tau
antibodies (e.g. AT8, AT180, and CP13) are prone to de-
tect signals in the axons of mice arising from anesthetic
administration and tissue temperature differences [33].
This effect was observed in C57BL6 wild type male
animals (i.e. harboring neither human tau, nor human
APP transgenes). Our results obtained with adolescent
C3H/C57BL6 wt mice extend previous observations by
Planel et al. (Additional file 4: Figure S4) and demon-
strate an effect of sodium pentobarbital administration
on the generation of phospho-tau species detected by
immunoblot. This effect was manifest in experiments
with a time-span of minutes from the time of anaesthetic
administration to the time of tissue harvest.
Cancino et al. [22] have disclosed that the use of frozen
vs. immersion-fixed tissue as an important variable within
their own dataset, with no tau immunostaining visible in
paraffin-embedded tissue. This is an interesting effect but
alone it cannot explain all divergent outcomes between two
prior studies [19,22]. Thus, unlike Wetzel et al., we were
unable to detect tau immunostaining in frozen sections
from compound transgenic mice (Figure 2A), while signal
was obtained in positive control (tau transgenic) animals.Also, this methodological issue has no bearing on our fail-
ure to detect insoluble forms of tau in biochemical ana-
lyses of frozen tissue samples (Figures 1 and 3). However,
the data presented here and these recent studies by
Cancino et al. [22] when taken together point to a gap in
the earlier studies that may have affected the conclusions
about P73’s role in AD pathogenesis [19].
Pathological forms of tau can be detected by histo-
chemical and immunostaining in paraffin-embedded
fixed tissue from human source material, as well as in a
number of animal models of tauopathy [1,11,15,21,28].
Indeed, use of fixed tissue preparations in conjunction
with silver staining procedures has been used to stage
the progressive changes as AD advances in severity [1].
Tau is naturally phosphorylated and it is possible to
hypothesize that labile over-phosphorylated forms of tau
could exist early in a disease process (such that their de-
tection is much dependent upon the applied protocol),
but with these species then evolving to highly aggregated
fibrillary material of the sort detected by standard histo-
chemical stains. However, this type of graded scenario
with qualitative and quantitative increments in severity is
not supported by the current data on Trp73 mice. Thus
there is no published evidence from compound transgenic
mice that suggest unusual tau species attributed to Trp73
hemizygosity evolve quantitatively and/or qualitatively with
time. Earlier reports [19,22] focus on compound transgenic
mice within a 2-week timeframe in adolescent mice and,
thus far, we have failed to find evidence of novel pathologies
in compound transgenic mice that differ from the parental
TgCRND8 mice (evaluations here at 45, 60, 70, 85 and 270
days of age; Figures 1 and 2, Additional file 1: Figure S1,
Additional file 2: Figure S2). Based on these considerations
we are led to consider whether immunostained structures
described in 45-60 day-old mice [19] do not represent the
Table 2 Association of AD with TP73 SNPs in 10 GWAS
datasets
SNP Position Alleles * RAF Meta P Direction
rs2821021 3,524,142 A/G 0.70 0.71 +–+-+-+-+
rs4648538 3,543,492 T/C 0.27 0.56 –+-+-+-++
rs4276857 3,544,345 T/C 0.73 0.57 ++-+-+-+–
rs1128474 3,545,611 G/A 0.78 0.22 -+-+—+–
rs1885864 3,554,987 T/C 0.19 0.24 +-+++++-++
rs3818330 3,555,427 T/G 0.19 0.24 +-+++++-++
rs12027041 3,591,447 C/G 0.47 0.98 +-++———+
rs3765770 3,635,980 A/G 0.036 0.76 -+++–++–
rs747828 3,636,225 T/C 0.96 0.78 +—++–++
rs747827 3,636,346 A/C 0.96 0.79 +—++–++
rs2236365 3,644,857 C/G 0.056 0.77 –++—++-
rs6664760 3,648,267 T/C 0.96 0.79 +—++–++
rs6695978 3,648,344 A/G 0.041 0.80 -+++–++–
rs9662633 3,649,561 A/G 0.057 0.64 -+++–++–
rs12562437 3,651,030 T/C 0.041 0.80 -+++–++–
rs10910018 3,651,408 A/G 0.042 0.83 -+++-+-+–
rs12117836 3,657,758 A/G 0.37 0.91 –+++–++-
rs2298222 3,659,656 A/G 0.30 0.80 —++–+++
rs3737589 3,662,844 A/G 0.63 0.88 ++—++–+
rs12120656 3,665,866 T/G 0.37 0.89 –+++–++-
rs4648554 3,668,003 T/C 0.63 0.91 ++—++–+
rs12128253 3,668,752 A/C 0.75 0.77 -++–++—
rs10797410 3,669,200 A/G 0.63 0.92 ++—++–+
rs10910022 3,669,499 A/G 0.97 0.74 +—++–++
rs1181889 3,671,026 T/C 0.88 0.95 +–++-+–+
rs1181888 3,671,790 A/G 0.88 0.93 +–++-+–+
rs12128669 3,676,076 T/C 0.25 0.78 —++–+++
rs1181885 3,676,566 T/C 0.11 0.81 -++–+-++-
rs1181884 3,676,597 T/C 0.88 0.81 +–++-+–+
rs12406474 3,676,771 T/C 0.75 0.83 +++–++—
rs1181883 3,677,932 T/C 0.61 0.66 +-+-+++–+
rs4648558 3,679,460 A/T 0.74 0.87 -++–++—
rs10910024 3,679,774 T/C 0.23 0.78 ++-++–+++
rs1181875 3,681,830 T/C 0.89 0.14 —++—+-
rs1181874 3,682,069 A/C 0.57 0.44 ++–+-+—
rs16824081 3,683,348 A/G 0.085 0.41 -+—+++-+
rs1181872 3,684,106 A/T 0.47 0.11 +++-+—+-
rs10910025 3,684,184 A/G 0.086 0.46 -+—+++-+
rs1181871 3,684,320 A/G 0.44 0.40 —+-+-+-+
rs1175551 3,688,644 T/C 0.44 0.41 —+-+-+-+
rs2275819 3,689,407 A/G 0.086 0.23 ++—+++-+
rs1175550 3,691,527 A/G 0.77 0.16 +–+-+++-+
rs1175549 3,691,726 A/C 0.75 0.44 +–+-+-+-+
Table 2 Association of AD with TP73 SNPs in 10 GWAS
datasets (Continued)
rs1891937 3,694,646 A/G 0.10 0.79 ++——++-+
rs2887275 3,695,110 C/G 0.10 0.79 ++——++-+
rs2799182 3,695,999 T/C 0.51 0.40 —+-+++-+
rs17411279 3,696,491 T/C 0.10 0.83 ++——++-+
rs3737593 3,696,535 A/G 0.88 0.65 -+++++–+-
rs8379 3,696,889 A/C 0.51 0.40 —+-+++-+
rs17411356 3,697,034 A/G 0.90 0.83 –++++–+-
rs17411384 3,698,223 C/G 0.10 0.83 ++——++-+
rs12563491 3,700,215 T/C 0.09 0.30 +——+++-+
rs2298228 3,700,849 C/G 0.98 0.66 -+++–+–+
rs2298227 3,701,662 T/C 0.88 0.64 -+++++–+-
Position = map position in base pairs; RAF = reference allele frequency; meta
P = meta analysis P-value; Direction = effect direction.
* Reference (risk) allele listed first.
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represent transient hyperphosphorylated forms of tau aris-
ing from an interaction between the P73 genotype and a
systematic effect of the conditions used for tissue harvest
and processing. This could explain the paradox as to how
Trp73+/- + TgCRND8 compound transgenic mice are
reported to have immunostaining of structures derived
from wt endogenous mouse tau at earlier ages than mice
overexpressing mutant forms of human tau [11,16,21,28].
Orthogonal data to appraise a hypothetical intersec-
tion of P73 biology and AD pathogenesis can be sought
from genetics. Previously the human TP73 gene was
described as having borderline significant association
with AD in a small dataset and that decreased p73 ex-
pression occurs in some cases of AD [23]. However only
tentative and un-replicated evidence for association with
AD in a subset of cases negative for the APOE ε4 allele
was reported (genotypic p-value = 0.02). Li et al. also
reported an allelic expression bias for p73 only in a sin-
gle control brain (not in AD samples) and that the allele
weakly associated with AD did not change the promoter
activity of TP73. Scacchi et al. [39] tested association of
AD with four TP73 SNPs, including two (rs227395 and
rs1801173), which form a putative functional haplotype,
another in the promoter region (rs3765728) and a syn-
onymous coding SNP (rs1801174). Marginal evidence of
association was obtained for rs3765728 (p=0.047) based
on a comparison of the rare G/G homozygote with the
other genotypes. There were no results for this SNP in
our study because it is an unproven SNP according to
build 131 of the HapMap database (http://www.ncbi.
nlm.nih.gov) and thus could not be imputed. Our meta-
analysis of 10 large AD GWAS datasets failed to show
an association between AD and any variants in the TP73
region. Furthermore, the TP73 locus failed to show sig-
nificant evidence for association in two other very large
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between TP73 and AD in a large sample strongly suggests
that variants in TP73 are unlikely to be a critical determin-
ant in the pathogenesis of AD. With regards to other var-
ieties of genomic alteration, one concept proposed by
Wetzel et al. [19] is that some individuals lose one copy of
the genomic locus encompassing the TP73 gene and,
consequently, that haploinsufficiency for TP73 may repre-
sent an AD susceptibility factor. This hypothesis was
based in part on a previous study of CNVs [24]. However,
in actuality, this report described un-validated CNVs in 95
individuals, the majority of whom were from a cancer-
screening program. Our data, derived from an AD case-
control sample comprising more than one thousand
individuals, failed to identify any CNVs in TP73.
Conclusions
Our investigation argues strongly against p73 as a locus
conferring genetic risk for AD pathology in mouse models
or in humans. While there is some evidence showing that
p73 haploinsufficiency may cause neurodegeneration in
mouse models by modulation of tau kinases, we found no
evidence for robust tau pathologies in tissue sections and
in biochemical fractionations of cell lysates from Trp73
haploinsufficient mice that deposit human Aβ peptide,
nor in aged deltaNp73 homozygous null mice, nor any
evidence that variants in the human TP73 gene influence
AD susceptibility. Overall, given the lack of evidence for
evolving pathology in Trp73+/- + TgCRND8 mice [19,22],
or discernible pathology (as here), and the failure of gen-
etic analyses to confirm an influence of Trp73 in human
cohorts, the concept of a significant role for P73 in AD
pathogenesis is not supported.
Materials and methods
Transgenic mouse studies
Mouse stocks and genotyping
Analysis of the Trp73 haploinsufficient mice and of the
DeltaNp73 mutant mice were performed at the Univer-
sity of Alberta, Edmonton, Canada and at the Université
Catholique de Louvain, Brussels, Belgium, respectively.
The Trp73 haploinsufficient mice described in the stud-
ies of Wetzel et al. [19] were obtained from the same
originator, Frank McKeon at Harvard University. The
mice were genotyped in a PCR involving three primers:
wt locus, 5’ GGG CCA TGC CTG TCT ACA AGA A 3’;
common wt region unaffected by gene targeting, 5’ CCT
TCT ACA CGG ATG AGG TG 3’; NEO gene, 5’ GAA
AGC GAA GGA GCA AAG CTG 3’ generating PCR
products of 600 bp and 400 bp for the wild type locus
and the interrupted allele respectively. PCR conditions
were 94°C 45 seconds, 64°C 45 seconds, 72°C 90 seconds
for 35 cycles with Platinum Taq polymerase (Invitrogen).
These mice (on the sixth backcross to C57BL6) wereintercrossed with the same TgCRND8 mice that were
also used by Wetzel et al. TgCRND8 mice [4] were
maintained on an outbred C3H x C57BL6 background.
Offspring were genotyped for the APP transgene array
by a PCR involving primers 5' TGTCCAAGATGCAG
CAGAACGGCTACGAAAA 3' lying in the human APP
coding region and 5’ AGAAATGAAGAAACGCCAAG
CGCCGTGACT 3’ lying within the 3’ untranslated re-
gion of the mRNA encoded by the Syrian hamster PrP
cosmid cos.Tet. transgene vector [42]. PCR conditions
were 94°C 30 seconds, 56°C 30 seconds 68°C 5 minutes for
35 cycles with Taq polymerase (Invitrogen) (Additional file
1: Figure S1). As an internal control for immunodetection
procedures (below) we employed the TgTau(P301L)23027
[28] or the Tg30 [29] lines of transgenic mice (in
Edmonton and Brussels, respectively) both expressing a 4-
repeat spliced form of human tau cDNA and developing
neurofibrillary tangles. These mice were genotyped with
the following primer pair: Primer 1572: 5' -TGG ATC
TTA GCA ACG TCC AGT CC 3' and Primer 1587: 5'
CTC TCC TCT CCA CAA TTA TTG ACC G 3'
representing exonic sequences that are not contiguous in
the mouse chromosomal tau locus but lie juxtaposed
within the tau cDNA insert in the cos.Tet transgene vec-
tor. DeltaNp73 mutant mice were described previously
[32] and maintained in a 129SvJ, C57BL/6 Background
according to European guidelines. All animal procedures
were approved by the animal ethics committees of the
University of Alberta and at the Université catholique de
Louvain.
Western blot analysis
Western blot analysis of tau species in tissue lysates and
detergent insoluble extracts were performed as described
previously [28]. 6E10 antibody (Sigma) was used for
immunodetection of APP by western blot (1:1000 dilu-
tion). t-tau antibody (Chemicon) was used at 1:1000 di-
lution for western blot analyses of all tau species. All
other tau antibodies were used at 1:500 for western blots,
with the exception of AT180 (epitope: phosphothreonine
231 and phosphoserine 235, 1:1000, Innogenetics). Other
antibody sources were AT180 and AT8 (phosphoserine
202 and phosphothreonine 205, Thermo Scientific). CP13
(phosphoserine 202), PHF-1 (phosphoserine 396/404)
and MC1 (a conformational-specific antibody recognizing
amino acid residues 5-15 and 312-322) were a gift from
Dr. Peter Davies.
Pathological analysis and immunohistochemistry
Trp73 haploinsufficient mice Mice were maintained in
accordance with Canadian Council for Animal Care
(CCAC) guidelines. Generally, brains were removed after
cerebral dislocation or anesthetic overdose (sodium
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saggital plane. Neutral-buffered formalin-fixed tissue
was batch processed on an automatic tissue processor
overnight with vacuum on each station to aid penetra-
tion. Paraffin sections were cut at 5 microns and affixed
to Fisherbrand Superfrost/Plus slides. Sections for
immunohistochemistry were blocked in Dako Dual En-
dogenous Enzyme-Blocking Reagent and normal goat
serum prior to incubation with primary antibody over-
night at 4°C and processing via the Dako EnVision+
Dual Link System-HRP kit with end products visualized
with DAB. For AT180 antibody, sections were processed
through an epitope retrieval step of immersion in 10 mM
citrate buffer pH6.0, 0.05% Tween 20, and heating in a
pressure cooker for 2 minutes. Sections were lightly
counterstained with hematoxylin, resin mounted and
images were acquired on a Nikon 90i microscope. For
processing by fluorescent microscopy mice were perfused
with PBS and fixed with 4% paraformaldehyde. Brains were
dissected, immersed overnight in fixative, rinsed with PBS
and transferred to 30% sucrose for 24 hours. Cryosections
were stored in an antifreeze solution (PBS:Glycerol:Ethyl-
ene Glycerol=2:1.5:1.5) before immunostaining. Sections
were washed with PBS, exposed to Dako Dual Endogenous
Enzyme-Blocking Reagent for 15 minutes, rinsed with 1x
PBS, blocked with 2% normal goat serum for 1 hour and
then incubated overnight with primary antibody (AT8, 1:50
or 1:100, as noted; CP 13, 1:50; MC1, 1:50; PHF1, 1:50;
6E10, 1:500) in antibody diluting solution. Subsequent to
PBS washes sections were incubated with secondary anti-
body (Alexa FluorW 594 goat anti-mouse IgG (H+L) at 0.01
mg/mL) for 2 hours at room temperature, PBS-washed
and mounted.
DeltaNp73 mutant mice Brains were removed after
transcardial perfusion of 4% paraformaldehyde in PBS
and were embedded in paraffin. 8 μm thick coronal
sections, prepared at various rostrocaudal levels, were
stained by immunohistochemistry with antibodies directed
against specific phosphotau epitopes (PHF-1 antibodies);
the signal was detected using a standard ABC kit. Sections
were also stained with the Gallyas silver staining method.
Human studies
Diagnostic, demographic and SNP data were obtained
from 10 genome-wide association study (GWAS) datasets
comprising a total of 8309 AD cases and 7366 controls
that constituted the discovery sample in a previously
published genome-wide association study (GWAS) of AD
by the Alzheimer Disease Genetics Consortium (ADGC)
[34]. The number of subjects in each dataset included in
the association analysis of TP73 SNPs is given in Table 1.
Appropriate local Institutional Review Board approvals
were obtained for all datasets. In addition, 1,093 Hispanicelderly [549 patients with late-onset AD (LOAD) and 544
controls] included in a GWAS conducted at Columbia
University (CU) was used to investigate copy number
variants (CNVs). Subjects in that study were self-reported
Hispanics and unrelated to other participants, and under-
went an in-person baseline interview on general health
and functional ability using a standardized assessment, in-
cluding medical history, physical and neurological examin-
ation and a neuropsychological battery. Each participant
was examined at 18 to 24 month intervals thereafter with
repeated interviews and examinations standardized to pre-
serve consistency. This dataset was not included in the
meta analysis of TP73 SNPs because the genetic make-up
of these individuals is distinct from European Caucasians
and we were unable to identify a suitable reference popu-
lation with haplotype data for genotype imputation. Ap-
propriate local Institutional Review Board approvals were
obtained for all datasets.
Copy Number Variant (CNV) analysis
The search for CNVs affecting the TP73 locus was done
in the CU dataset from array intensity files as previously
described [43]. Briefly, the CNV analysis was performed
using at least two software packages (iPattern and either
PennCNV or QuantiSNP). CNVs identified by two inde-
pendent algorithms have a >95% chance of being
true positives and could be prioritized for follow-up
validation.
Statistical analysis
TP73 encompasses an approximately 80 kb region on
chromosome 1. For the purpose of genetic association
analysis, we evaluated all SNPs located in the transcribed
region and within 2000 base pairs of the start and end
sites of the gene. A total of 91 genotyped and well-
imputed (r2>0.3) SNPs with minor allele frequencies >
0.01 in the TP73 gene were identified, but only 54 of these
were included in the analysis because marker information
was not available for the other SNPs in all 10 datasets. As-
sociation of TP73 SNPs with AD was evaluated by com-
parison of allele frequencies and with an additive model
using logistic regression. We tested an additive model
using a logistic regression framework developed in R to
compute the strength of the association of disease status
with dosage of the risk allele. Familial data in the MIR-
AGE study was analyzed separately and in two ways. The
discordant siblings were analyzed using a family-based al-
lelic association test, as implemented in FBAT [44]. SNP
genotypes in the MIRAGE dataset were evaluated using
generalized estimating equations (GEE) [45] in the R pack-
age [46]. While this population-based test is sensitive to
population stratification, we found no evidence that popu-
lation substructure was associated with disease in this
sample (evaluated by regressing disease on the first 10
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We report the results of association from the GEE frame-
work because the FBAT were limited by low power from
uninformative, small nuclear families. The GEE results
from the testing of the additive model were used in the
meta-analysis for consistency across datasets. In order
to obtain a robust estimate of association in the
combined datasets, we conducted a meta-analysis of the
p-values for the additive model from the 10 Caucasian
datasets using the METAL software (http://www.sph.
umich.edu/csg/abecasis/Metal/index.html). This soft-
ware implements an inverse-variance meta-analysis to
combine the association results across datasets. It sums
the regression coefficients weighted by the inverse vari-
ance of the coefficients. The meta-analysis p-value of
the association is then obtained from the summarized
test statistic. The Versatile Gene-based Association
Study (VEGAS) approach [48] was used to summarize
the strength of association of TP73 with AD based on
the number of SNPs tested in the gene and size of the
gene. This method computes a gene-based test statistic
based on the SNP p-values within the gene, and then
uses simulation to calculate an empirical gene-based
p-value.Additional files
Additional file 1: Figure S1. Longer exposure of western blot shown
in the first column of Figure 1A from 45 days-old animals. See Figure 1.
Again, “+/-“ in the case of Trp73 and APP indicates that these mice were
heterozygous for null allele and hemizygous for the TgCRND8 APP
transgene array, respectively.
Additional file 2: Figure S2. Cerebral cortex in control and compound
transgenic mice aged 70 days. The left-hand column shows a control
TgTauP301L mouse. No tau immunostaining is seen in 70 day-old
compound mutant animals (2nd column) with AT8, CP13, MC1 and AT180
antibodies. The cortex of this animal is however positive for Aβ-
containing amyloid plaques (6E10 antibody, data not shown). Aged
matched Trp73+/- and TgCRND8 littermate controls also do not present
any tau immunostaining, as illustrated in the 3rd and 4th columns,
respectively. All panels, 10 x objective.
Additional file 3: Figure S3. Biochemical analyses of soluble tau
species in aged compound and Trp73 hemizygous mice. Western blot
analyses of phospho-specific tau species in soluble protein fractions
obtained after fractionation of homogenates from sagittally-sectioned
hemi-brains. Protein samples were derived from animals at 270 days of
age. Tau antibodies, AT8, AT180, CP13 and PHF1 (rows 1-4, respectively),
were used to evaluate pathological forms of tau in the samples while the
APP-specific 6E10 antibody was used to confirm the presence of the APP
transgene (row 5). A tau transgenic sample (left-hand lane) was included
in the immunoblot series as a positive control (TgTauP301L mouse, age
540 days). An actin immunoblot serves as loading control in the soluble
fraction (row 6).
Additional file 4: Figure S4. Western blot analyses of phospho-specific
tau species in insoluble protein fractions obtained from anaesthetic
treated or control C3HxC57 F1 mice. Western blot analysis was with CP13
and PHF1 antibodies. Genders are denoted by either “f” (female) or “m”
(male). “Control” represents euthanasia by cervical dislocation, “Na-
pentob” represents euthanasia by overdose with sodium pentobarbital.
Loading controls were as per Figures 1 and 3.Additional file 5: Table S1. Association of TP73 SNPs with AD in the
GWAS datasets.
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